Regulatory

CLINUVEL
Posted by CLINUVEL
May 10, 2022

CLINUVEL progresses vitiligo study

CLINUVEL today announced that it will start treatment of vitiligo patients with...

Read More
CLINUVEL
Posted by CLINUVEL
May 6, 2022

Notification regarding unquoted securities

Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 28, 2022

Appendix 4C & Activity Report

CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...

Read More
CLINUVEL
Posted by CLINUVEL
April 27, 2022

Notice of ceasing to be a substantial holder

Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 7, 2022

Initial Director’s Interest Notice

Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 4, 2022

CLINUVEL appoints new Non-Executive Director

Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 23, 2022

Change of Director's Interest Notice

Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
March 2, 2022

Change of Director's Interest Notice

Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
February 23, 2022

CLINUVEL Reports Record December Half Year Operating Profit

Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
February 23, 2022

Appendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report

Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 19, 2022

Change of Director’s Interest Notice

Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
January 19, 2022

Notification of Cessation of Securities

Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...

Read More
Lachlan Hay
Posted by Lachlan Hay
November 8, 2021

CLINUVEL Expands Pharmaceutical Portfolio

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders

Read More
CLINUVEL
Posted by CLINUVEL
November 8, 2021

CLINUVEL Adds ACTH to Portfolio

Melbourne, Australia, 08 November 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
October 8, 2021

Appendix 4G & Corporate Governance Statement

Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More